학술논문
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial
Document Type
Article
Author
Source
In: The Lancet Haematology . (The Lancet Haematology, January 2024, 11(1):e38-e50)
Subject
Language
English
ISSN
23523026